Drug intelligence / Profile preview

Path-002

Development stage: Preclinical
Lead developer: PATH Biotech
Modality: Small Molecules

Overview

Path-002 is a preclinical-stage small molecule drug candidate being developed by PATH Biotech for the treatment of Alzheimer's disease. Discovered using the company's proprietary AI-driven precision medicine platform, Path-002 is part of a series of candidates (including Path-001, Path-003, and Path-004) targeting neurodegenerative pathology. While the specific molecular target and mechanism of action have not been publicly disclosed, the program focuses on leveraging AI to identify novel therapeutic pathways for complex brain disorders.

Beyond the preview

Go deeper on Path-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Path-002.

Explore the full profile